What is H.C. Wainwright's price target for PCRX?

H.C. Wainwright's latest stated price target for Pacira BioSciences Inc. (PCRX) is $90, from its action on Feb 25, 2022.

What is H.C. Wainwright's rating on PCRX?

H.C. Wainwright rates PCRX Buy, a bullish rating, as of Nov 17, 2025.

When did H.C. Wainwright last change its view on PCRX?

On Nov 17, 2025, H.C. Wainwright starts coverage at Buy.

Analyst firms · H.C. Wainwright · PCRX

H.C. Wainwright PCRX price target and rating history

Pacira BioSciences Inc. (PCRX) · Health Care

H.C. Wainwright rates Pacira BioSciences Inc. (PCRX) Buy with a $90 price target, as of its latest action on Nov 17, 2025. It has published 5 rating actions on PCRX since August 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.

Current rating: Buy
Price target: $90
Median target, all firms: $29
Actions on PCRX: 5

H.C. Wainwright price target on PCRX

H.C. Wainwright price target on PCRX, each point a stated target, August 2021 to February 2022.

Every H.C. Wainwright rating on PCRX

Nov 17, 2025
InitiateH.C. Wainwright starts coverage at Buy
Feb 25, 2022
ReiterateH.C. Wainwright raises its price target to $90 from $86, keeps Buy
Nov 4, 2021
ReiterateH.C. Wainwright raises its price target to $86 from $80, keeps Buy
Oct 12, 2021
ReiterateH.C. Wainwright cuts its price target to $80 from $84, keeps Buy
Aug 4, 2021
ReiterateH.C. Wainwright cuts its price target to $84 from $86, keeps Buy

How other firms rate PCRX

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Oppenheimer	Outperform	$32	Sep 23, 2026
Leerink Partners	Market Perform	$28	Sep 9, 2026
Truist Securities	Buy	$30	Aug 17, 2026
Barclays	Equal Weight	$27	Dec 9, 2025
H.C. Wainwright	Buy		Nov 17, 2025

Questions about H.C. Wainwright and PCRX

What is H.C. Wainwright's price target for PCRX?: H.C. Wainwright's latest stated price target for Pacira BioSciences Inc. (PCRX) is $90, from its action on Feb 25, 2022.
What is H.C. Wainwright's rating on PCRX?: H.C. Wainwright rates PCRX Buy, a bullish rating, as of Nov 17, 2025.
When did H.C. Wainwright last change its view on PCRX?: On Nov 17, 2025, H.C. Wainwright starts coverage at Buy.
How does H.C. Wainwright's PCRX target compare with other analysts?: Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.

More PCRX rating histories

All H.C. Wainwright ratings PCRX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.